Sonoma Pharmaceuticals (NASDAQ:SNOA) Announces Earnings Results

Sonoma Pharmaceuticals (NASDAQ:SNOA) issued its earnings results on Wednesday. The company reported ($0.59) EPS for the quarter, Zacks reports. Sonoma Pharmaceuticals had a negative net margin of 27.21% and a negative return on equity of 59.58%.

Sonoma Pharmaceuticals Price Performance

Shares of NASDAQ SNOA traded down $0.03 during midday trading on Wednesday, reaching $2.66. The company’s stock had a trading volume of 17,300 shares, compared to its average volume of 56,988. The stock has a market capitalization of $3.56 million, a P/E ratio of -0.53 and a beta of 1.43. Sonoma Pharmaceuticals has a 12-month low of $2.44 and a 12-month high of $9.37. The firm has a 50 day moving average price of $2.69 and a 200-day moving average price of $2.36.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.